1. Home
  2. BCG vs AYTU Comparison

BCG vs AYTU Comparison

Compare BCG & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.69

Market Cap

32.6M

Sector

N/A

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.01

Market Cap

27.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
AYTU
Founded
2016
N/A
Country
United States
United States
Employees
150
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.6M
27.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BCG
AYTU
Price
$1.69
$2.01
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
80.2K
46.9K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$43.75
P/E Ratio
$56.15
N/A
Revenue Growth
N/A
277.47
52 Week Low
$1.36
$1.46
52 Week High
$3.44
$3.07

Technical Indicators

Market Signals
Indicator
BCG
AYTU
Relative Strength Index (RSI) 35.88 22.11
Support Level $1.46 $1.85
Resistance Level $1.90 $2.64
Average True Range (ATR) 0.19 0.12
MACD -0.04 -0.05
Stochastic Oscillator 5.62 4.62

Price Performance

Historical Comparison
BCG
AYTU

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: